Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Preparation method of L-erythro biopterin compound

A biopterin and compound technology, which is applied in drug combination, organic chemistry, metabolic diseases, etc., can solve the problems of complex operation, difficult purification, expensive raw materials, etc., and achieve the effects of reducing environmental pollution, shortening reaction routes, and reducing production costs

Active Publication Date: 2021-02-23
SHANGHAI FOREFRONT PHARMA CO LTD
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] However, there are major defects in this industrial route: 1) the synthesis of the key intermediate 5-deoxy-L-arabinose needs to be condensed into acetal by using L-rhamnose and ethanethiol with strong odor, complicated operation and pollution Seriously, it is no longer used in industry; 2) The intermediate 5-deoxy-L-arabinose itself is unstable and cannot be stored for a long time. Most of them are oils, and they are all unstable, so it is necessary to use the crude product to push all the way from C to L-erythrobiopterin, which makes the process difficult to control quality and carry out GMP production; 4) adopt 5-deoxy-L-arabinose Derivatives are condensed with 2,4,5-triamino-6-hydroxypyrimidine (TAP) to prepare L-erythro-biopterin, which has poor selectivity, many impurities, and low yield; 5) the generated L-erythro-biopterin , because of its extremely poor solubility in common solvents and extremely difficult purification, its quality directly and negatively affects the quality of subsequent hydrogenation to prepare sapropterin hydrochloride
[0012] According to the current technology, most of the process improvement of L-erythro-biopterin compounds in the world is still in the preparation of 5-deoxy-L-arabinose, especially the use of other reagents to replace mercaptans to reduce odor and pollution; there is no significant progress on the condensation of 5-deoxy-L-arabinose derivatives and TAP, and the raw materials are expensive, the route is long, and the yield is low, resulting in high production costs and low safety performance, which cannot meet the requirements of modern pharmaceutical industry production. need

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method of L-erythro biopterin compound
  • Preparation method of L-erythro biopterin compound
  • Preparation method of L-erythro biopterin compound

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0192] Wherein, the definition of each substituent is as above, and will not be repeated here. The preparation method of L-erythrotype biopterin compound shown in formula (I) comprises the following steps:

[0193] (1) compound shown in formula (VI) and Carry out Sonogashira reaction, make the compound shown in formula (V);

[0194] (2) compound shown in formula (V) is through catalytic hydrogenation, makes the compound shown in formula (IIa);

[0195] (3) The compound shown in formula (IIa) is subjected to dihydroxylation reaction to obtain the compound shown in formula (IV);

[0196] (4) compound shown in formula (IV) is through cyclization reaction, makes the compound shown in formula (I-1), and the compound shown in formula (I-1) is hydrolyzed, makes the L- shown in formula (I) Erythro-biopterin compounds.

[0197] In the above (1)-(4), the specific introduction of each reaction is as above, and will not be repeated here.

[0198] understandable when R 4 for-COOR 5...

Embodiment 1

[0222]

[0223] Weigh 200mg compound 8, 11mg CuI, 10mg PdCl 2 , 30mg PPh 3 Place in a 25mL three-neck flask, and add 5mL of acetonitrile. 0.7 mL of triethylamine and 1.1 mL of propyne (1M in THF) were added under stirring at room temperature, and the reaction was stirred for 16 h. 10 mL of water was added to quench the reaction, the layers were separated, and the organic layer was dried and concentrated to obtain 163 mg of crude compound 6, which was used in the next reaction. IR (cm -1 )ν3400, 2226, 1647, 1487, 1192; 1 H NMR (400MHz, DMSO-d 6 )δ8.26(s,1H),7.54(s,2H),2.01(s,3H), 13 C NMR (101MHz, DMSO) δ155.61, 150.33, 128.08, 115.71, 111.16, 88.27, 76.62, 4.18. HRMS m / z (ESI+) C 8 h 7 N 4 + requires: 159.0667; found: 159.0671.

[0224]

[0225] Add 62mg Na to 10mL MeOH and stir until complete reaction, then add 226mg guanidine hydrochloride N 2 Protected, stirred at room temperature for 5min. The insoluble matter in the system was filtered, and 163 mg of com...

Embodiment 2

[0240]

[0241] Disperse 200mg of compound 5 in 5mL of an aqueous solution containing 50mg of NaOH, heat to 78°C, stir for 1h, add acetic acid dropwise to neutralize the system to pH=5-6, filter the precipitated solid, and wash with methanol to obtain compound 5-1 (152mg, purity 98%, yield 76%);

[0242] Dissolve 152mg of compound 5-1 in a combined solution of 5mL MeOH / DCM=1 / 1, stir well to dissolve, add 100mg of Lindlar Pd, replace H 2 (1 atm) stirred at room temperature for 3 days. After filtering the catalyst, the solvent was concentrated to obtain compound 3 (150mg, purity 95%, yield 93%); 1 H NMR (500MHz, DMSO) δ12.3(s, 1H), 8.53(s, 1H), 6.49(s, 2H), 2.04(s, 3H). 13 C NMR (125MHz, DMSO) δ161.85, 156.13, 150.79, 148.55, 136.37, 127.07, 92.12, 85.24, 4.59. HRMS m / z (ESI+) C 9 h 10 N 5 o + requires:203.2050,found:203.2051

[0243]

[0244] Compound 3 is subjected to a dihydroxylation reaction, including the following methods:

[0245] 1) Sharpless asymmetric di...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a preparation method of an L-erythro biopterin compound, wherein the L-erythro biopterin compound has a structure as shown in a formula (I), and the L-erythro biopterin compound as shown in the formula (I) is mainly prepared from a compound with a structure as shown in a formula (II) or a formula (III) through a dihydroxylation reaction. The preparation method of the L-erythro biopterin compound is high in production efficiency, low in cost, green, environmentally friendly and suitable for industrial production.

Description

technical field [0001] The invention relates to the technical field of medicine preparation, in particular to a preparation method of L-erythrotype biopterin compounds. Background technique [0002] Formula (I) indicates that L-erythro-biopterin compounds are important intermediates of most drugs at present, especially sapropterin drugs. For example: (R)-2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydro-4( 3H)-pteridinone (BH4), which is an essential coenzyme in hydroxylation reaction and oxygenase in organisms, is the most important coenzyme of nitric oxide synthase (NOS), and its hydrochloride (i.e. dihydrochloride sapyl Pterin, whose structural formula is formula (I-3)) has been approved by many countries for the treatment of phenylketonuria. [0003] [0004] And the main method of synthesizing sapropterin dihydrochloride at present is to obtain by hydrogenation reduction of the compound shown in formula (I-1). [0005] [0006] Therefore, how to safely...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D475/04A61P3/00
CPCC07D475/04A61P3/00
Inventor 不公告发明人
Owner SHANGHAI FOREFRONT PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com